BOX 1-1 Congressional Request for CDC Anthrax Vaccine Research, FY 2000–1
Public Law 106-113 provided fiscal year 2000 funding
“to the Centers for Disease Control and Prevention (CDC) for a collaborative effort to study the safety and efficacy of vaccines used against biological agents. The study would address: (1) the risk factors for adverse events, including differences in rates of adverse events between men and women; (2) determining immunological correlates of protection and documenting vaccine efficacy; and (3) optimizing the vaccination schedule and administration to assure efficacy while minimizing the number of doses required and the occurrence of adverse events. It is intended that NIH, CDC, and the Department of Defense will fully cooperate in this effort.”
The excerpt of Public Law 106-113 above is the language that formed the basis of the contract for this project. In the succeeding year, Congress made additional comments as follows in the House–Senate conference report that was generated in conjunction with fiscal year 2001 appropriations legislation, with fiscal year 2001 funding provided by Public Law 106-554.
“Regarding the anthrax study, the conferees understand that clinical studies will be greatly facilitated by the establishment of the Vaccine Healthcare Center Network, with the first site at Walter Reed Army Medical Center. This Network will facilitate data collection, standardization of the anthrax immunization, training and general data collection for this project.”